Washington University Researchers Develop Modular Antibody Strategy to Combat Tumor Drug Resistance
Researchers at Washington University School of Medicine in St. Louis have introduced a new modular 'click-to-assemble' strategy to enhance cancer drug efficacy. This approach, detailed in a study published in Nature, involves a bioorthogonal ligation strategy that creates a dual-targeting antibody-drug conjugate (ADC). This method improves tumor uptake and therapeutic efficacy, particularly in pancreatic, gastric, and breast cancer models. The strategy allows existing antibodies to be repurposed, enhancing treatment responses by targeting multiple tumor antigens simultaneously. The study demonstrated that this approach could slow or halt tumor progression even in cases where conventional ADCs fail due to low or heterogeneous HER2 expression. 
